The $25.7 billion of revenues earned reflects 82% of operational growth; excluding contributions from Comirnaty and Paxlovid drugs, the revenues increased 2% operationally. PFE expects Cominaty to bring in roughly $32 billion for the full year 2022 despite the mentioned unfavorable foreign exchange impact.
Unique stance on Ukraine
On the war in Ukraine Bourla commented:
Chart and analysts’ predictions
Shares have been trading in a choppy manner since the start of 2022, with Covid lockdowns being slowly eased and most of the population across the globe vaccinated. Perhaps investors thought that the Covid rally the stock has had is over. Recently PFE broke above the 20-day Simple Moving Average; however, major resistance lines could be said to nest around $54. Despite solid earnings, no significant volume increase has been noticed while the stock popped ‘only’ 2% throughout the day. On Wall Street, analysts give the stock a moderate buy rating; however, those having a hold rating on the stock are in the majority as compared to the buy crowd. For the next 12 months, the average price prediction is at $59.62, which is 21.49% above the current trading price of $49.08. Few could have predicted such a rise in revenue from PFE, but the company managed to pull it off. With a dividend yield of 3.26%, investors that already own shares of the company had plenty of reasons to smile about; with increasing revenue, the dividend should be safe and steadily growing. Furthermore, Pfizer and other vaccine producers could be an interesting field for investment if warnings of more frequent pandemics actually come true. Regardless PFE seems to be on a solid footing; investors should take into consideration that strong earning companies should do well long-term. Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
